REXULTI (Otsuka America Pharmaceutical, Inc.)
Welcome to the PulseAid listing for the REXULTI drug offered from Otsuka America Pharmaceutical, Inc.. This Atypical Antipsychotic [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Otsuka America Pharmaceutical, Inc. |
NON-PROPRIETARY NAME: | brexpiprazole |
SUBSTANCE NAME: | BREXPIPRAZOLE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Atypical Antipsychotic [EPC] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2015-07-10 |
END MARKETING DATE: | 0000-00-00 |
REXULTI HUMAN PRESCRIPTION DRUG Details:
Item Description | REXULTI from Otsuka America Pharmaceutical, Inc. |
LABELER NAME: | Otsuka America Pharmaceutical, Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 0.25(mg/1) |
START MARKETING DATE: | 2015-07-10 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 59148-035_9d263d31-21bf-4b5d-8893-b7ccc3c3fe0c |
PRODUCT NDC: | 59148-035 |
APPLICATION NUMBER: | NDA205422 |
Other BREXPIPRAZOLE Pharmaceutical Manufacturers / Labelers: